Filter
66
Filtered Results: 66
Text search:
DNDi
-
Drugs
for
neglected
diseases
initiative
Featured
Recommendations
8
New Publications
6
Language
Document type
Studies & Reports
25
No document type
14
Strategic & Response Plan
6
Manuals
5
Resource Platforms
5
Guidelines
3
Videos
3
Fact sheets
3
Situation Updates
1
Infographics
1
Countries / Regions
Global
8
Latin America and the Carribbean
5
Colombia
3
Africa
3
Ethiopia
3
Kenya
2
West and Central Africa
2
East and Southern Africa
2
Southern Africa
2
Asia
1
Uganda
1
Brazil
1
India
1
Authors & Publishers
Publication Years
Category
Studies & Reports
4
Guidelines
3
Hepatitis
2
Pediatrics
2
Statistics
2
Leishmaniasis
2
COVID-19
1
Virology
1
Chagas
1
Medical Devices & Equipment
1
Policies
1
Drugs & Medical Equipment
1
NTDs & Others
1
Parasitology
1
Human African Trypanosomiasis
1
Non-communicable Diseases
1
HIV & STI
1
Disease Prevention & Control
1
Pharmacy & Technologies
1
Toolboxes
Studies & Reports
8
Strategies & Roadmaps
5
Capacity Building & Resources
4
Clinical Aspects & Diagnostics
4
Studies & Reports
4
Studies & Reports
4
Local Action
2
Essential Medicines
2
Clinical Aspects & Diagnostics
2
Information & Education Material (IEC)
2
Statistics & Facts
2
NTDs General
2
Clinical Aspects, Treatment & Prevention
1
Treatment & Prevention
1
Introduction to Global Health
1
Concepts of Global Health
1
Curricula & Core Competencies
1
Children
1
Health Equity & Equality
1
Country specific documents
1
Long COVID/ Post-COVID Syndrome
1
Advocacy & Communication
1
Prices and Patents
1
Capacity Building & Resources
1
Clinical Aspects & Diagnostics
1
Information & Education Material (IEC)
1
Overview, Studies & Reports
1
Mycetoma, Chromoblastomycosis & other deep mycosis
1
Information & Education Material (IEC)
1
Asia and Pacific
1
Human Rights & the Right to Health
1
Antiretroviral Treatment ART
1
AMR
1
Reports & Studies
1
Mycetoma is a slow-growing bacterial or fungal infection, most often of the foot, that may spread to other parts of the body and can cause severe deformity. It is a debilitating disease that most often affects poor people in rural areas with limited access to health care.
This is a summary of the following peer-reviewed, scientific article:
Comparative Evaluation of Immunoassays to Improve Access to Diagnosis for Chagas Disease in Colombia.
A Iniciativa Medicamentos para Doenças Negligenciadas (DNDi) é uma organização internacional sem fins lucrativos que disponibiliza medicamentos seguros, eficazes e acessíveis para doenças negligenciadas, desde o laboratório até sua chegada às mãos das populações mais vulneráveis do mund...
L’initiative Médicaments contre les Maladies Négligées (DNDi) est une organisation internationale à but non lucratif spécialisée dans la recherche, le développement et la mise à disposition de traitements sûrs, efficaces et abordables aux patients les plus négligés.
La Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi) es una organización internacional sin fines de lucro que proporciona tratamientos seguros, eficaces y asequibles para los pacientes más desatendidos, desde el laboratorio hasta su llegada a las manos de las poblaciones más vulnerables ...
Die Initiative Medikamente gegen vernachlässigte Krankheiten (Drugs for Neglected Diseases initiative, DNDi) ist eine internationale gemeinnützige Organisation, die sichere, wirksame und bezahlbare Behandlungen für die am meisten vernachlässigten Patient:innen erforscht, entwickelt und bereitste...
Accessed on 04.04.2023
The Drugs for Neglected Diseases initiative (DNDi) is an international
non-profit organization that discovers, develops, and delivers safe,
effective, and affordable treatments for the most neglected patients
DNDi is now striving to make fexinidazole available to the majority of people who have T.b. gambiense sleeping sickness. We are supporting a three-year access and pharmacovigilance study that began in 2020 and have so far carried out in-country training of relevant staff in 250 hospitals and...
DNDi’s long-term goal for sleeping sickness, also known as human African trypanosomiasis (HAT), is to develop and register two new drugs that are effective against both Stage 1 and Stage 2 of the disease and both subspecies of the parasite, T.b. gambiense and T.b. rhodesiense. T.b. rhodesiense is ...
Chagas is a parasitic disease that affects over 6 million people in the
world. As the disease typically remains asymptomatic for years, new cases
often go unnoticed and unreported, and most people with the disease
are unaware of their condition. Less than 10% of people affected are
diagnosed and...
Leishmaniasis is among the most neglected diseases. The most common form is cutaneous leishmaniasis that forms lesions on the skin.
The only treatment available for cutaneous leishmaniasis is highly toxic. In some cases, patients have died because of the treatment, even though cutaneous leishmania...
Leishmaniasis is a climate-sensitive disease. Changes in
temperature, rainfall, and humidity can have strong impacts on
the sandfly vector, altering their distribution and influencing their
survival and population sizes. Increased temperatures shorten
vector development time, reduce Leishmania p...
Website last accessed on 14.04.2023
Health workers Luke (Kenya), Juliana (Colombia), and Shishu (India) share the same hope for their patients with leishmaniasis: simple, oral treatments. For the first time ever, it seems leishmaniasis research is moving from neglect to a sense of hope.
Full Perscribing information on Fexinidazole Tablet for oral use
INDICATIONS AND USAGE
Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati...
1 billion people are at risk of infection with leishmaniasis, a neglected disease strongly linked to poverty. There’s no single, simple cure: current treatments are complex and need to be adapted to the form of the disease and geographical region.
At the forefront of DNDi’s efforts to develop new treatments is the need to understand the realities and treatment needs of patients and health care staff in the field. The ultimate goal for human African trypanosomiasis (HAT) is a truly simplified
treatment which can be orally administered, impl...
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...
The Leishmaniasis East Africa Platform (LEAP) was established to support the generation of scientific evidence for the development and distribution of new treatments for leishmaniasis in Eastern Africa.
Diabetes Poster - Does your child show any of these symptoms?
La enfermedad de Chagas es parasitaria y afecta a más de 6 millones
de personas en el mundo. Como normalmente es asintomática durante
años, los nuevos casos suelen no detectarse ni reportarse y la mayoría
de las personas con la enfermedad no tiene conciencia de su condición.
Se diagnostica ...
